IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Has Average Target Price of $727.69

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have been given a consensus rating of “Moderate Buy” by the thirteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $719.55.

A number of analysts have recently weighed in on IDXX shares. Citigroup boosted their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Barclays lowered their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. BTIG Research dropped coverage on shares of IDEXX Laboratories in a report on Friday, October 30th. They issued a “buy” rating on the stock. Morgan Stanley boosted their target price on shares of IDEXX Laboratories from $805.00 to $810.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, The Goldman Sachs Group began coverage on shares of IDEXX Laboratories in a report on Friday, October 16th. They set a “buy” rating and a $740.00 price target for the company.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $672.04 on Friday. IDEXX Laboratories has a fifty-two week low of $500.61 and a fifty-two week high of $769.98. The business has a 50-day moving average of $538.81 and a two-hundred day moving average of $573.69. The stock has a market capitalization of $52.94 billion, a P/E ratio of 45.32 and a beta of 1.55. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 0.87.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same period last year, the business earned $3.22 EPS. The firm’s revenue was up 9.9% compared to the same quarter last year. On average, equities research analysts predict that IDEXX Laboratories will post 15.05 EPS for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the transaction, the director owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.79% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IDXX. Arlington Trust Co LLC raised its stake in shares of IDEXX Laboratories by 46.3% in the second quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after acquiring an additional 19 shares during the last quarter. Bell Investment Advisors Inc grew its stake in shares of IDEXX Laboratories by 45.5% during the third quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock valued at $33,000 after purchasing an additional 20 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC grew its stake in shares of IDEXX Laboratories by 21.4% during the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 119 shares of the company’s stock valued at $67,000 after purchasing an additional 21 shares during the last quarter. Arlington Capital Management Inc. grew its stake in shares of IDEXX Laboratories by 4.8% during the first quarter. Arlington Capital Management Inc. now owns 479 shares of the company’s stock valued at $269,000 after purchasing an additional 22 shares during the last quarter. Finally, Valeo Financial Advisors LLC raised its position in IDEXX Laboratories by 6.4% in the 2nd quarter. Valeo Financial Advisors LLC now owns 383 shares of the company’s stock worth $202,000 after purchasing an additional 23 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

More IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Third-quarter results beat expectations: IDEXX reported adjusted earnings of $3.96 per share versus $3.71 expected, while revenue rose about 10% year over year to $1.21 billion, above estimates. Recurring diagnostics sales to veterinarians were a key growth driver. IDXX Q3 Earnings & Revenues Surpass Estimates
• Positive Sentiment: The company raised its full-year 2026 outlook, projecting EPS of $14.96–$15.16, above the $14.86 consensus, and revenue of $4.7–$4.8 billion, versus expectations of about $4.7 billion. The higher forecast reinforces optimism after the quarterly beat. IDEXX raises forecast
• Positive Sentiment: Morgan Stanley maintained an Overweight/Buy view and raised its price target to $810, signaling further potential upside in the analyst’s assessment. Morgan Stanley stock recommendations
• Positive Sentiment: A technical analysis report said IDXX moved above its 200-day moving average, a signal some investors interpret as supportive of a longer-term upward trend. IDXX crossed above the 200-day moving average
• Negative Sentiment: Analysts noted that veterinary visits remain lackluster, creating a challenging demand backdrop. IDEXX’s results were strong despite this, but the company is relying on diagnostics growth to offset softer visit trends. UBS on IDEXX’s results and vet-visit backdrop

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.